Scholar Rock Holding 과거 수익 실적

과거 기준 확인 0/6

Scholar Rock Holding의 수입은 연평균 -25.3%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 19.3%의 비율로 증가했습니다. 매출은 연평균 25.1%의 비율로 감소해 왔습니다.

주요 정보

-25.3%

수익 성장률

-2.9%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	-25.1%
자기자본 수익률	-285.3%
순이익	n/a
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07

수익 및 비용 분석

Scholar Rock Holding 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:SRRK 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Sep 24	0	-226	62
30 Jun 24	0	-204	59
31 Mar 24	0	-183	54
31 Dec 23	0	-166	49
30 Sep 23	0	-159	47
30 Jun 23	0	-160	44
31 Mar 23	0	-166	43
31 Dec 22	33	-135	43
30 Sep 22	37	-131	43
30 Jun 22	43	-125	43
31 Mar 22	47	-112	42
31 Dec 21	19	-132	40
30 Sep 21	18	-122	38
30 Jun 21	16	-109	35
31 Mar 21	15	-97	32
31 Dec 20	15	-86	28
30 Sep 20	20	-71	26
30 Jun 20	21	-64	24
31 Mar 20	22	-57	23
31 Dec 19	20	-51	21
30 Sep 19	13	-54	20
30 Jun 19	8	-49	17
31 Mar 19	3	-51	16
31 Dec 18	0	-49	14
30 Sep 18	0	-43	11
30 Jun 18	0	-38	9
31 Mar 18	0	-29	6
31 Dec 17	0	-25	5
31 Dec 16	0	-16	4

양질의 수익: SRRK 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SRRK 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SRRK 은(는) 수익성이 없으며 지난 5년 동안 연간 25.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SRRK 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SRRK 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SRRK 현재 수익성이 없기 때문에 마이너스 자본 수익률( -285.33% )을 갖습니다.

Scholar Rock Holding 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Recent updates

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Price target increased by 11% to US$29.75

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock Announces Chief Executive Officer Changes

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Price target decreased to US$29.00

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Consensus revenue estimates increase by 75%

Consensus revenue estimates increase by 75%

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Scholar Rock Holding Corporation Provides Pipeline Updates

Price target decreased to US$44.67

Price target decreased to US$46.17

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Price target decreased to US$55.80

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CFO & Head of Business Operations exercised options and sold US$2.8m worth of stock

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)